Media centre
Contact the Global Media Team
Contact the Global Media Team
All contacts
US Media Team
Press releases and articles
All
Items 75
-
Professor David Goldstein to lead AstraZeneca’s genomics initiative as Chief Adviser
-
AstraZeneca appoints David Goldstein as Chief Adviser for its genomics initiative
-
Innovative pancreatic research expands treatment horizons for people with type 2 diabetes
-
Liquid biopsy: plasma ctDNA testing moves into mainstream cancer treatment
-
AstraZeneca provides update on cediranib EU marketing authorisation application
- Corporate Press Release
-
Patients at the core of partnership
-
Peripheral Patients? PAD (peripheral arterial disease) Policy Initiative
-
Can ‘drag and drop’ cancer simulation speed up drug discovery?
-
Phase III combination trial of Bydureon and Forxiga shows significant benefits in patients with type-2 diabetes
- Corporate Press Release
-
Opening up a treasure trove of new drug target opportunities
-
AstraZeneca recognised as a leader in 2016 Dow Jones Sustainability Indices (DJSI)
-
AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure
- Corporate Press Release
-
PEPFAR and AstraZeneca launch partnership across HIV and hypertension services in Africa
-
Benralizumab phase III trials show positive results in severe asthma
- Corporate Press Release
-
AstraZeneca completes commercialisation agreement with Aspen for anaesthetics portfolio
- Corporate Press Release
-
AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016
- Corporate Press Release
-
AstraZeneca to sell small molecule antibiotics business to Pfizer
- Corporate Press Release
-
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
- Corporate Press Release
-
Breakthrough research revealing novel drivers of cardiometabolic diseases published in Science
-
Uncovering world’s first structural clues to inhibiting an emerging DNA Damage Response target area for future anti-cancer therapy
-
AstraZeneca provides update on Phase III trial of Selumetinib in non-small cell lung cancer
- Corporate Press Release
-
H1 2016 Results
- Corporate Press Release
-
AstraZeneca files first clinical trial application in Moderna messenger RNA collaboration
-
AstraZeneca’s antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia
- Corporate Press Release
-
AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of Type 2 diabetes
- Corporate Press Release
-
Tagrisso met primary endpoint in phase III 2nd-line lung cancer trial
- Corporate Press Release
-
AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
- Corporate Press Release
-
New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
- Corporate Press Release
-
AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
- Corporate Press Release
-
AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio
- Corporate Press Release
-
AstraZeneca and Foundation Medicine enter strategic collaboration for Lynparza companion diagnostic assay
- Corporate Press Release
-
AstraZeneca completes US licensing agreement with Ironwood Pharmaceuticals for lesinurad
- Corporate Press Release
-
New study published in ‘Cancer Cell’ furthers understanding role of CXCR2 in pancreatic cancer
-
AstraZeneca’s Faslodex met primary endpoint in first-line treatment of advanced breast cancer
- Corporate Press Release
-
Positive CHMP opinion in EU for saxa/dapa (saxagliptin and dapagliflozin) for adults with type-2 diabetes
- Corporate Press Release
-
Clinical trial data unveil a driver of FGFR inhibitor response in gastric cancer
-
AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalaemia
- Corporate Press Release
-
AstraZeneca highlights continued progress of oncology pipeline at 2016 ASCO Annual Meeting
- Corporate Press Release
-
AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer
- Corporate Press Release
-
AstraZeneca announces positive results from benralizumab phase III programme in severe asthma
- Corporate Press Release
-
Defining a new approach to developing nanomedicines for cancer therapies
-
Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
- Corporate Press Release
-
AstraZeneca to highlight the breadth of its respiratory medicines at American Thoracic Society 2016 International Conference
- Corporate Press Release
-
AstraZeneca Commissions New Report on Global Stroke Burden
-
AstraZeneca joins life science leaders to support UK's continued membership of the EU
-
AstraZeneca and Lieber Institute for Brain Development publish discovery of novel protein associated with schizophrenia
-
AstraZeneca supports World Ovarian Cancer Day 2016
-
AstraZeneca completes divestment of Imdur to China Medical System Holdings
- Corporate Press Release
-
AstraZeneca completes acquisition of Takeda’s respiratory business
- Corporate Press Release
-
Q1 2016 Results
- Corporate Press Release
-
Positive CHMP opinion for CAZ AVI in the EU for serious bacterial infections
- Corporate Press Release
-
New genomic classification approach strengthens early cancer trial design
-
AstraZeneca enters into US licensing agreement with Ironwood Pharmaceuticals for lesinurad
- Corporate Press Release
-
New studies published in Nature Immunology further understanding of immune system
-
AstraZeneca launches integrated genomics approach to transform drug discovery and development
- Corporate Press Release
-
AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting
- Corporate Press Release
-
AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease
- Corporate Press Release
-
AstraZeneca to showcase clinical and scientific leadership in lung cancer at ELCC 2016
- Corporate Press Release
-
Pandemic influenza vaccine receives positive CHMP opinion
- Corporate Press Release
-
Brilinta preferred over clopidogrel in updated American College of Cardiology and American Heart Association guideline in acute coronary syndrome
- Corporate Press Release
-
Tagrisso™ (osimertinib) approved in Japan for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer
- Corporate Press Release
-
AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke
- Corporate Press Release
-
AstraZeneca’s potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation
- Corporate Press Release
-
MedImmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A
- Corporate Press Release
-
AstraZeneca enters into agreement with ProStrakan for rights to Moventig in Europe
- Corporate Press Release
-
AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine
- Corporate Press Release
-
AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma
- Corporate Press Release
-
Acalabrutinib recommended for orphan drug designation in Europe for three indications
- Corporate Press Release
-
Zurampic (lesinurad) approved in the European Union for patients with gout
- Corporate Press Release
-
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
- Corporate Press Release
-
Durvalumab granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer
- Corporate Press Release
-
AstraZeneca and MedImmune enter consortium to deliver new treatments for chronic kidney disease
- Corporate Press Release
-
AstraZeneca and BIND Therapeutics publish AZD2811 ACCURINS® data in Science Translational Medicine
-
Full-Year and Q4 2015 Results
- Corporate Press Release
-
TAGRISSO™ (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer
- Corporate Press Release
